dasatinib have different side effect profiles. The aim of this study was to investigate costs of adverse events (AEs) in patients receiving recommended doses of nilotinib or dasatinib for treatment of chronic and accelerated CML. METHODS: Incidence rates of grade 3/4 AEs in CML patients treated with nilotinib or dasatinib were obtained from clinical trial data. Direct medical costs for non-hematological AEs and for grade 4 anemia and thrombocytopenia, and febrile neutropenia were obtained from Ontario Case Costing Initiative (OCCI) inpatient databases and were specific to oncology patients. Costs for grade 3 anemia, thrombocytopenia, and non-febrile neutropenia were assumed to be outpatient costs and were based on literature and expert validation of treatment pathway and resource utilization in the Canadian context. Multivariate sensitivity analyses were conducted on costs of AEs and for an alternative dasatinib dosing (100 mg). RESULTS: Cost of treatment-related AEs for CML patients was highest for dasatinib. Total costs for AEs associated with the accelerated phase were higher than those associated with the chronic phase: $19,902 versus $7,653 for dasatinib and $8,645 versus $3,790 for nilotinib, respectively. Ranking observed among treatments for base case costs of AEs was maintained for both high and low cost estimates, and for 100 mg dasatinib dosing, indicating that the model was robust to variation in these parameters. CONCLUSION: For patients resistant or intolerant to imatinib, costs of dasatinib-related AEs were approximately twice the costs of nilotinib-related AEs in both chronic and accelerated phases, highlighting the importance of considering the cost of AEs in economic evaluation of tyrosine kinase inhibitors. Further research is needed to evaluate the impact of AEs on health care expenditures. We developed a probabilistic decision model of cost-effectiveness for lung cancer (LC) screening with helical computed tomography (hCT) compared with chest x-ray (CXR) and no screening (NS) given uncertain efficacy and risks of screening in practice. METHODS: Markov model comparing NS to CXR and hCT screening in 60-year old current smokers screened annually until age 75 as base case using published literature, Surveillance Epidemiology and End Results database, and Mayo Clinic data. In the base case, we assumed stage shifts observed with screening translate into survival benefits. Sensitivity analyses evaluated cohort ages for starting and stopping screening, screening compliance, smoking status, positive nodule management and treatment costs. An expected value of perfect information analysis (EVPI) was estimated to determine the value of further research to reduce current uncertainty. RESULTS: In the base case, CXR cost $51,245/QALY vs. NS and hCT was dominated by CXR. The probability that CXR is cost-effective was 94.3% at a maximum acceptable ratio of $100,000/QALY (4.8% and 0.9% for NS and hCT, respectively). EVPI analysis suggested that at a maximum ICER of $100,000/QALY, further research would potentially be worth $55 million for the US population over ten years. When it was assumed that hCT screening did not result in any false positives necessitating invasive surgery, hCT cost $119,571/QALY vs. CXR. CXR cost $137,652 vs. NS for former smokers and was dominated by NS for never smokers; hCT was dominated in both these analyses. Results were sensitive to age at annual screening initiation and termination. CONCLUSIONS: Assuming stage shifts observed with LC screening translate into survival benefits, hCT was, as expected, most efficacious, but also had the highest false positive rate. The associated detrimental cost and quality of life effects resulted in hCT being dominated by CXR (less efficacious but more specific). To examine the cost-effectiveness of introducing an HPV-16/18 prophylactic cervical cancer (CC) vaccine in a setting of existing screening in Portugal. METHODS: A Markov cohort simulation model was used with an annual cycle length and which mimics the natural history of HPV infection to CC. The analysis was undertaken from the health care system perspective. Direct medical costs were estimated and discounted at a rate of 3%. Effect measures were: CC cases and deaths avoided, life years saved and QALYs, discounted at a rate of 3%. The incremental cost-effectiveness was estimated by comparison of the options to be implemented with the current strategy. The analytic horizon was lifetime where subjects enter the model at 10 years old and are followed for 95 cycles until death. One-way sensitivity analysis was conducted on the key variables. RESULTS: Our results predicted that an HPV-16/18 vaccine targeting 12-year-old girls would be cost-effective and could reduce lifetime CC cases and mortality by 92% compared with current screening. Vaccination was predicted to substantially reduce the number of oncogenic HPV infections and Cervical Intraepithelial Neoplasia cases (CIN1-3 cases). The additional cost of generating one QALY by implementing a vaccination strategy, where all 12-year-old girls are vaccinated with a vaccine showing 96.7% efficacy against HPV-16/18, was €13,810. The results were sensitive to alternative assumptions about the discount rate and age at which vaccination begins. The base-case strategy was robust to modifications in vaccination coverage and fairly robust to changes in both percentages of oncogenic HPV and of opportunistic screening rates. CONCLUSION: The analysis suggested that prophylactic cervical cancer vaccination could have a substantial public health benefit. A vaccine directed specifically at reducing the incidence of oncogenic HPV types 16 and 18, during the peak ages of infection, could be expected to be economically attractive. 
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PCN32 COST-EFFECTIVENESS ANALYSIS OF AN HPV-16/18 PROPHYLACTIC CERVICAL CANCER VACCINE IN A SETTING OF EXISTING SCREENING IN PORTUGAL-RESULTS FROM A MATHEMATICAL MODEL
Pereira JA 1 , Barbosa C 1 , Mateus C 1 , Standaert B 2 1 Universidade Nova de Lisboa, Lisboa, Portugal, 2 GlaxoSmithKline Biologicals, Rixensart, Belgium OBJECTIVE: To examine the cost-effectiveness of introducing an HPV-16/18 prophylactic cervical cancer (CC) vaccine in a setting of existing screening in Portugal. METHODS: A Markov cohort simulation model was used with an annual cycle length and which mimics the natural history of HPV infection to CC. The analysis was undertaken from the health care system perspective. Direct medical costs were estimated and discounted at a rate of 3%. Effect measures were: CC cases and deaths avoided, life years saved and QALYs, discounted at a rate of 3%. The incremental cost-effectiveness was estimated by comparison of the options to be implemented with the current strategy. The analytic horizon was lifetime where subjects enter the model at 10 years old and are followed for 95 cycles until death. One-way sensitivity analysis was conducted on the key variables. RESULTS: Our results predicted that an HPV-16/18 vaccine targeting 12-year-old girls would be cost-effective and could reduce lifetime CC cases and mortality by 92% compared with current screening. Vaccination was predicted to substantially reduce the number of oncogenic HPV infections and Cervical Intraepithelial Neoplasia cases (CIN1-3 cases). The additional cost of generating one QALY by implementing a vaccination strategy, where all 12-year-old girls are vaccinated with a vaccine showing 96.7% efficacy against HPV-16/18, was €13,810. The results were sensitive to alternative assumptions about the discount rate and age at which vaccination begins. The base-case strategy was robust to modifications in vaccination coverage and fairly robust to changes in both percentages of oncogenic HPV and of opportunistic screening rates. CONCLUSION: The analysis suggested that prophylactic cervical cancer vaccination could have a substantial public health benefit. A vaccine directed specifically at reducing the incidence of oncogenic HPV types 16 and 18, during the peak ages of infection, could be expected to be economically attractive. is not cost-effective as its cost per Quality-Adjusted-LifeYear (QALY) is more than three times the magnitude of the GNP per head. Adoption of a thrice a lifetime PAP screening strategy dominates (ie: costs less and adds more QALYs) the current strategy, which opportunistically gives PAP screens to 12.2% of females annually. However, because of the inevitable future fall in the HPV vaccine price, it is not recommended to abandon the current opportunistic PAP smear strategy for a more systematic thrice a lifetime strategy. When should the HPV vaccination be adopted? Assuming non-waning efficacy, HPV vaccinations become cost effective when cost falls below $97 per dose, become very cost-effective (ie: cost per QALY < per capita GNP) when cost falls below $50 per dose and become cost-saving (ie: gains in decreased treatment costs exceed increased screening, program and training costs) when cost per dose falls below the $27.20 threshold. After HPV vaccination is adopted, should we still have screening programs? Expansion of the PAP program to a pentaannual PAP program would provide the most additional QALYs within cost-effectiveness constraints. CONCLUSION: PAP compliancy should be increased to 20.0% per annum, both before and after the vaccination is introduced. An HPV vaccination program should be adopted when the vaccine price drops to a level that it becomes affordable to the Ministry of Health or falls below $20.44 per dose, providing a cost-saving incentive to the health insurance funds.
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PCN34 COST-EFFECTIVENESS OF GEFITINIB FOR FIRST-LINE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER: A MARKOV MODEL-BASED ANALYSIS
Liu PH 1 , Hu FC 2 , Wang JD 1 1 National Taiwan University, Taipei, Taiwan, 2 National Taiwan University Hospital, Taipei, Taiwan OBJECTIVE: Gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is a new treatment option for non-small cell lung cancer (NSCLC). Some studies have found better clinical outcomes for gefitinib treatment in women, neversmokers, certain mutation in the tumor EGFR gene, and patients with adenocarcinoma and in East Asian ethnicity. However, gefitinib is currently regarded as a salvage treatment rather than a first-line option. The objective of this study was to assess the cost-effectiveness of gefitinib for first-line treatment of the inoperable, chemo-naïve NSCLC patients in Taiwan.
METHODS:
We developed a Markov model of the cost, quality of life, survival, and incremental cost-effectiveness of the alternative option with gefitinib for first-line treatment, as compared with current practice of platinum-based chemotherapy regiments. Variables of clinical effectiveness were determined from corresponding trials. The economic analysis adopted the health care payer's perspective, and only direct medical costs were taken into account. RESULTS: Use of gefitinib for first-line treatment had a better mean survival than platinum-based chemotherapies (13.1 versus 11.6 months) while increasing lifetime cost. Given the base-case assumptions, we found that gefitinib increased life expectancy by 1.49 months, or 0.80 quality-adjusted months, at an estimated cost of $4,140 per treated patient, for an incremental costeffectiveness ratio (ICER) of $62,100 per quality-adjusted lifeyear (QALY). The ICER would decrease to $48,600 per QALY gained when such analysis was applied to a subgroup of patients with molecular marker of EGFR exon 19 deletion or L858R mutations while they had a significantly longer mean survival of 20.8 months. Sensitivity analyses showed that this ICER remained below $100,000 per QALY for all model variables.
CONCLUSION:
Use of gefitinib for first-line treatment has a cost-effectiveness ratio below $50,000 per QALY gained in advanced NSCLC patients with preferred clinical characteristics in which a significant extension of overall survival has been demonstrated. Bristol-Myers Squibb Pharmaceutical, Wallingford, CT, USA OBJECTIVE: Currently imatinib resistant or intolerant CML patients have minimally effective therapies available. Dasatinib binds to the protein Bcr-Abl; it binds also to active and inactive forms of protein, while imatinib binds only to the inactive forms. Therefore, mutations that affect the active form can lead to resistance to imatinib. A Markov model was built to evaluate the long-term cost-effectiveness of dasatinib in the treatment of adult CML patients, after resistance or intolerance to imatinib. METHODS: The model consists of an initial within-trial period in which best response rates observed from the clinical trials are used. Response was defined as best response of complete hematologic response (CHR), minor cytogenetic response (CyR), minimal CyR, partial CyR, and complete CyR. The model simulates patients moving between health states using progression probabilities derived from the literature and BMS clinical trials. The time horizon was the lifetime of patients in the cohort, allowing evaluation of life expectancy and lifetime costs. Brazilian costs and health resource estimates were applied to the treatment of the different phases of CML. RESULTS: For CML patients in CP dasatinib provided 0.66 QALYs per patient and the ICER was R$80,000 with an additional life expectancy of 0.98 years. In the case of AP dasatinib provided an additional life expectancy of 3.48 years with a ICER of R$91,000. And in the BP dasatinib provided an additional life expectancy of 1.91 years with a ICER of R$123,000. CONCLUSION: The CE analysis showed that dasatinib is more cost-effective in the resistant or intolerant patients than imatinib in the three phases of CML with increased life expectancy with quality. Though there is an incremental cost associated to the treatment with dasatinib, the cost is related to longer life expectancy and therefore expenditure of more resources.
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